Systematic review of systemic therapy for advanced or recurrent endometrial cancer

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 158-167

  Carey, Mark S ^a   Gawlik, Christine ^a   Fung Kee Fung, Michael ^b,d   Chambers, Alexandra ^c,d   Oliver, Tom ^c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Program in Evidence based Care   (Canada)

Author keywords

Chemotherapy; Endometrial cancer; Systematic review; Systemic therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MELPHALAN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BLOOD TOXICITY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; EDEMA; ENDOMETRIUM CANCER; EVALUATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMOLYTIC UREMIC SYNDROME; HORMONAL THERAPY; HUMAN; LEUKOPENIA; MEDLINE; MESENTERIC ARTERY OCCLUSION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SEPSIS; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS;

EID: 33644520595     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.019     Document Type: Review

References (27)

1. National Cancer Institute of Canada Canadian Cancer Statistics 2004 2004 Toronto, Ontario
2. R.J. Lotocki, L.J. Copeland, A.D. DePetrillo, and W. Muirhead Stage I endometrial adenocarcinoma: treatment results in 835 patients Am. J. Obstet. Gynecol. 146 1983 141 145
3. H.D. Homesley, R.C. Boronow, and J.L. Lewis Jr. Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals, 1949-1965 Obstet. Gynecol. 47 1976 100 105
4. L. Elit, and H. Hirte Novel strategies for systemic treatment of endometrial cancer Expert Opin. Investig. Drugs 9 2000 2831 2853
5. A.D. Santin, S. Bellone, T.J. O'Brien, S. Pecorelli, M.J. Cannon, and J.J. Roman Current treatment options for endometrial cancer Expert Rev. Anticancer Ther. 4 4 2004 (Aug) 679 689
6. J.T. Thigpen, M.F. Brady, R.D. Alvarez, M.D. Adelson, H.D. Homesley, and A. Manetta Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group J. Clin. Oncol. 17 1999 1736 1744
7. P.J. Hoskins, K.D. Swenerton, J.A. Pike, F. Wong, P. Lim, and C. Acquino-Parsons Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J. Clin. Oncol. 19 2001 4048 4053
8. M.A. Dimopoulos, C.A. Papadimitriou, V. Georgoulias, L.A. Moulopoulos, G. Aravantinos, and D. Gika Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study Gynecol. Oncol. 78 2000 52 57
9. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G. Reid, and A. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 22 2004 2159 2166
10. G.F. Fleming, V.L. Filiaci, R.C. Bentley, T. Herzog, J. Sorosky, and L. Vaccarello Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma: Gynecologic Oncology Group study Ann. Oncol. 15 2004 1173 1178
11. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, and R.A. Burger Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 22 2004 3902 3908
12. M.S. Aapro, F.H. van Wijk, G. Bolis, B. Chevallier, M.E.L. Van der Burg, and A. Poveda Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group Ann. Oncol. 14 2003 441 448
13. H.H. Gallion, V.L. Brunetto, M. Cibull, S.S. Lentz, G. Reid, and J.T. Soper Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study J. Clin. Oncol. 21 2003 3808 3813
14. B. Weber, F. Mayer, P. Bougnoux, T. Lesimple, F. Joly, and M. Fabbro What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results [abstract] Proc. Am. Soc. Clin. Oncol. 22 2003 453
15. A. Pawinski, S. Tumolo, G. Hoesel, A. Cervantes, A.T. van Oosterom, and G.H. Boes Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. European Journal of Obstetrics Gynecol. Reprod. Biol. 86 1999 179 183
16. H.J. Long, R.A. Nelimark, and S.S. Cha Comparison of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) vs doxorubicin and cisplatin (AC) in advanced endometrial carcinoma [abstract] Proc. Am. Soc. Clin. Oncol. 14 1995 282
17. J.T. Thigpen, J.A. Blessing, P.J. DiSaia, E. Yordan, L.F. Carson, and C. Evers A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 12 1994 1408 1414
18. J.H. Edmonson, J.E. Krook, J.F. Hilton, G.D. Malkasian, L.K. Everson, and J.A. Jefferies Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma Gynecol. Oncol. 28 1987 20 24
19. C.J. Cohen, H.W. Bruckner, G. Deppe, J.A. Blessing, H. Homesley, and J.H. Lee Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study Obstet. Gynecol. 63 1984 719 726
20. J. Horton, P. Elson, P. Gordon, R. Hahn, and R. Creech Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens Cancer 49 1982 2441 2445
21. J. Horton, C.B. Begg, J. Arseneault, H. Bruckner, R. Creech, and R.G. Hahn Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer Cancer Treat. Rep. 62 1978 159 161
22. K.J. Pandya, B.Y. Yeap, L.M. Weiner, J.E. Krook, J.K. Erban, and R.A. Schinella Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882) Am. J. Clin. Oncol. 24 2001 43 68
23. J.T. Thigpen, M.F. Brady, R.D. Alvarez, M.D. Adelson, H.D. Homesley, and A. Manetta Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group J. Clin. Oncol 17 1999 1736 1744
24. G.M. Rendina, C. Donadio, M. Fabri, P. Mazzoni, and P. Nazzicone Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma Eur. J. Obstet. Gynecol. Reprod. Biol. 17 1984 285 291
25. J. Ayoub, P. Audet-Lapointe, Y. Methot, J. Hanley, R. Beaulieu, and R. Chemaly Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status Gynecol. Oncol. 31 1988 327 337
26. G.B. Kristensen, I. Vergote, E. Eisenhauer, G. Baekelandt, G. Stuart, and E. Aavall-Lundquist First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival J. Clin. Oncol. 22 2004 5003
27. M.E. Randall, V.L. Brunetto, H. Muss, N. Mannel, N. Spirtos, and F. Jeffrey Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group [abstract] Proc. Am. Soc. Clin. Oncol. 22 2003